Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sarissa now owns 8% of the stock - latest 13F:
https://fintel.io/so/us/amrn/sarissa-capital-management-lp
Sarissa Capital Management LP ownership in AMRN / Amarin Corp - ADR
2023-12-05 - Sarissa Capital Management LP has filed an SC 13D/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 33,470,000 shares of Amarin Corp - ADR (US:AMRN). This represents 8.2 percent ownership of the company. In their previous filing dated 2023-09-05 , Sarissa Capital Management LP had reported owning 29,300,000 shares, indicating an increase of 14.23 percent.
But I'm not sure about what they actually owned before - most sites show they only had 10.5M shrs as of 9/30/2023. And Sarissa wasn't even the top shareholder end of Q3 - Kynam Capital Management is, with 12M shrs - who the heck are they? Looks like another private equity firm, and they've doubled their # AMRN shrs over the last 12 months - they're underwater bigtime.
Only way this stock is getting to $10 is via a 1:20 reverse split.......which will put most shareholders cost basis so high they will never come close to recovering more than a few percent of their investment - have had it happen to me several times, losses range from 95% to 99% - since I consider that money gone, I just hold the stock in case some miracle occurs - like ARNA coming back from the dead and getting a BO by PFE years after they did a 1:10 RS. But I only invested a fraction of the money in those compared to AMRN so they didn't kill my portfolio's value like AMRN has done. If I hadn't imposed a max investment amount limit in AMRN on myself I would be in major retirement trouble - and boy was I tempted to buy more for a time, mostly because I personally knew how great the drug was..
Interesting - most of the generics got approval for 1 g caps in 2020, but they all didn't get approval for the 0.5 g cap until sometime this year - that's why I thought none of them sold the 0.5 mg dose - I didn't check various 2024 Medicare plans to see if they covered the 0.5 mg dose this year because I'm back on the 1 g dose. So Strides got the ANDA approved then licensed it to Amneal? That's a tad odd - their COGS will be higher than other generics because of that licensing fee.
I don't think "pay to delay" generic deals are legal anymore - even if they are, it's way too late for AMRN to try that, needed to do it the second they lost the patent case and generics had ANDAs approved. They can't afford to do anything anymore - they've cut US reps to the bone and are AFAIK still posting GAAP losses despite all the cost cutting.
I know pharmacies prefer to go with a generic maker who has many products so they can do the package deal you mention - but CVS at least must have deals with several generic makers, because two of the generic drugs I take look different almost every other prescription fill - they are definitely coming from diff manufacturers. The one scrip I get at Giant is the same, pill shapes/sizes/colors change all the time.- even stranger is that there are several doses for that one and the middle dose pill is tiny like a BB, but the 50% smaller dose for that one is quadruple the size - all filler, I guess to make it easier to take it, but that doesn't explain why the bigger dose is so tiny. So with all of these GV makers now I think there's a decent chance you might get Teva's GV one month and Apotex the next - that's even worse than having to take GV to start with - I guarantee you every GV do not act the same, meaning they might have shorter or longer times to peak serum EPA levels - FDA only cares about total area under the curve, not peak levels and when they occur.
I don't even know what this means from that SA blurb:
I'm pretty sure NVAX is still losing money, never had a profitable quarter despite the OWS windfall - delays in getting the vaccine made killed them, lots of money wasted on upgrading existing mfg facilities they never used or couldn't get FDA qualified, sales volume was miserable even after they got EUA - and they're the only ones that are still not FDA approved - MRNA and PFE got full approval. The CEO got fired last year for incompetence - NVAX was the laughingstock of the biotech world for a while there because they couldn't do anything right. I can understand you dumping it, all they had in 2019 was a flu vaccine, and they actually finished that P3 several years ago, had decent results, but never filed an NDA - just bizarre. BTW, they had a 1:20 RS, not 1:10 - twice as bad.
Yes, I found Humana's 2024 plan on medicare.gov yesterday, but thanks for mentioning it anyway - once my deductible is met a month of V will only cost me $73. Oh wait - you mentioned an Advantage Plan - I can't join one of those HMO type plans because none of my doctors are in their network of providers, neither is the hospital only 10 mins from my house - if I had a heart attack and went to the closest in-plan hospital it would take almost 30 mins to get there - time to get to a hospital is critical when you have an MI, minutes count - could be the diff between life and death.
Found something even more disturbing looking at Cigna 2024 commercial and Medicare plans - for commercial plans V is stilled covered as a cholesterol drug, but the tiers range from T2 ($3 copay) to T4 (47% copay), varies by state - nobody is going to get it in states where it's T4, that's $200/mo out of pocket. This morning I didn't log into Cigna, just went to their "looking for a plan" page as a guest - this is what I found when I entered V as my only prescription:
They are offering GV instead of V for Part D plans, which is clearly patent infringement for the R-IT indication - problem is the formularies for 2024 and prior years simply list it under "LIPID/CHOLESTEROL LOWERING AGENTS" - I don't think it's ever been on their list as "CARDIOVASCULAR AGENTS", so proving R-IT infringement would be difficult. GV is listed under "LIPID......" and it's T4, $200/mo copay - but GV was not available on their 2023 formulary, now it is - since TG lowering drugs have lost a lot of coverage (no generic Lovaza) Cigna adding GV for 2024 can only mean it's for R-IT.
As far as delisting and going to the OTC or pinks market, yeah it's not the end of the world but some brokers won't let clients buy penny stocks on those exchanges (TDA will but it costs you $7/trade). The problem with OTC stocks is they have very limited SEC reporting requirements, next to nothing, so you have no idea what the balance sheet looks like, what they're spending on SG&A, what COGS is - nada. There *are* some foreign stocks with large market caps on the OTC market - all of these have MC's in the billions, with Tencent's MC being a whopping:$375B USD:
Luckin Coffee Inc. (LKNCY), the Chinese coffee chain
Tencent Holdings LTD (TCEHY), the Chinese multimedia company
DiDi Global Inc. (DIDIY), the Chinese mobility technology platform
SAP SE (SAPGF), the German software company
There's no reason for companies that big to be on the OTC market except they want to avoid SEC scrutiny and filing 10-Q's or annual reports - quite common for Chinese stocks.
How exactly do you think AMRN can regain compliance with NASDAQ listing requirements wrt to trading under $1 for a period of time? There is zero indication the market will push the pps above $1, so a RS is close to inevitable - and as I mentioned a RS usually wipes out long time owners, cost basis goes so high. I once owned the shipper DRYS, which did eight ]reverse stock splits between March 2016 and July 2017 (it was a racket run by the DRYS CEO and a VC firm, Kalani Investments to steal the company from investors, to this day still can't believe it was legal, or rather that no one got prosecuted for securities fraud) - before my position was reduced to zero after one of those RS's, my basis had soared to $72k/shr!
Citigroup probably had the most famous (or infamous) RS of all time - it was widely held and had a huge MC - if you had the misfortune of buying it between 2001 and 2007 around $40-$50 or more you got wiped out - a May 2011 1:10 RS pushed the pps up from $4 to $40, but you now had 1/10th the number of shrs - a $10k investment at $50/shr (200 shrs) turned into 20 shrs at $40/shr worth a piddling $800 today - that other money ($9200) is gone forever - there are very few ARNA's out there that eventually thrived after a RS. I found an old study that tracked stocks with RS's from 1995 to 2011 and it showed only 29% survived at least 5 yrs post-RS, avg. survival time for those that went under was < 3 yrs. But that's ancient data, don't know what the numbers are if you include RS's up to 2022, but I seriously doubt the numbers got any better, probably got worse because SPACs and reverse mergers didn't exist before 2011 - a large number of them are just scams. If you own a stock that undergoes a RS you can pretty much kiss your money goodbye - I have two stocks that had big RS's to stay listed, one was a 1:20 RS, the other a massive 1:400 RS - I'm down 99% in both, should just dump them to clean up my "balance sheet" because neither one is going to survive, one is already just an empty shell company, but I hang onto them as a reminder to never invest more than a few grand in a spec stock.
My current #%$* Cigna Secure Rx (PDP) has COMPLETELY dropped coverage for V in 2024 - WTF?!?! This is terrible news if other insurers are following suit! Looks like I'm going back to my old Part D provider, Humana Basic Rx Plan (PDP) - copay for 1 mo of 1 g V is only $73, a very good price. Anyone else looking for Part D plans finding other insurers who have dropped V coverage for R-IT indication?
I cringe to think about what happens to this stock if more insurers stop covering V - they're already going to have to do a RS to stay listed, no new country approvals are coming before the 180 day clock for delisting expires. So glad I found and take the drug, but wish to hell I'd never bought so much stock, or rather wish I wouldn't have paid so much for my first few lots (low double digits) - after a RS I will never get back to even - just a 1:4 RS would give the shrs in my IRA a cost basis of frigging $26.64, higher than the stock has every traded for since I heard about it in 2011 But at this point a 1:4 RS is just delaying the inevitable, another RS - they'll need something like a 1:8 RS to get the pps back over $5, which is an important number - anything less than $5 is officially a penny stock regardless of market cap, and most funds won't invest in penny stocks. I had a similar disaster with ARNA but came out of that debacle with a 140% profit after holding for 12 yrs because they developed a new drug (the one I bought it for flopped and caused a 1:10 RS) that PFE wanted badly enough that they ponied up $100/shr for ARNA - no such miracle is coming for AMRN, no pipeline - the combo drug is never gonna get to a P2, let alone approved, too many variables in statins and doses to make a one size fits all combo drug.
As a freeloader I can't search the board to see if a RS has been discussed, although I'm sure it's come up - if there's one particularly informative thread about a RS I'd appreciate it if someone could provide me a link to the first post of that thread, want to see what some of the other long time longs think about it. Lots of people here now have joined since I stopped reading this board, so y'all keep your traps shut - you don't know me (I'm one of the original board members) and I don't want to read accusations of being a short - and you'll just make yourself look stupid - old timers know I'm been long since 2011.
Appreciate the well wishes and apologize for going off on you yesterday - after a 3 day struggle between CVS and my doc, which involved trips or long wait time phone calls to talk to a pharmacist I was pretty PO'd about the whole ordeal. Last night when I put that 1st 1 g cap into my mouth with a swig of water my brain instantly remembered choking on the last one I took 5 yrs ago and my throat/stomach tightened up in fear - I sat down, took a big breath, and got the two caps down one at a time. That fear of god from almost choking to death alone in my house left a big mental scar - having multiple health problems and living alone scares my various PTs and they share their fear with me - I don't NEED anyone else pointing out I could be in big trouble if I got hurt and couldn't get to a phone - I know what the risks are and there's nothing I can do about it unless your beautiful 38 yr old sister wants to move in with me . They all want me to buy one of the "I've fallen and I can't get up" transmitters and wear it around my neck, but they're an expensive service and I can't stand having any type of jewelry on my body - a fob hanging on a chain from my neck is a non-starter, I couldn't tolerate it, would drive me insane.
Anyway, this morning I was paying close attention to what was on the radio when I was taking my morning meds instead of what thinking about was going into my mouth, tossed both 1 g caps in at the same time and they went down no problem because I wasn't thinking about what I was swallowing - doesn't hurt that I haven't had a gagging incident in years. The 1 g V caps were not the only pills I take that caused gagging problems in the past, but I was eventually able to replace almost all of them with smaller pills from a different company except for one vital amino acid DS I take twice a day. Back in my gagging/choking days I needed the Heimlich maneuver twice in one year while playing golf when one of those big hard pills got stuck sideways in my throat, scared the crap out of my playing partners (and me of course).
Dude, that gagging problem from 4-5 yrs ago before you were even posting here, caused by the 1 g caps getting stuck sideways in my throat, causing me to CHOKE - I could have died from a blocked airway - and I threw them up the next day after gagging again, then I started gagging on all meds and DS's I take (a bunch), even started gagging on FOOD, so I stopped eating almost completely, nothing would stay down. I lost 35 lbs (from 200 lbs, 6'2") in a month, down to literal skin and bones until we got my gagging under control - part of the solution was the 0.5 g caps.
Don't criticize when you have no idea what you're talking about - especially when you don't understand how serious a major gag reflex problem can get - it's like unintentional anorexia - you know, the disease that killed Karen Carpenter via starvation? (if you're old enough to remember her)
As far as why do I think this is costing AMRN money, did you even bother to think about it before you replied? The last time I checked 1 g V cost $350 retail, 0.5 g $450 retail - back when Liz was still around (you're too new here to even remember her) I emailed her complaining about the price diff and she said AMRN intentionally charged more for the small ones because they KNEW some people had problems swallowing the 1 g caps and were willing to pay up for smaller caps. Rebates and discounts are a % of the diff between WAC and retail, they're not a fixed dollar amount - just pull a number out of thin air and say AMRN's revenues are reduced 50% combined for all of those deductions - that means they get $50/scrip less for the 1 g caps. You really don't think that's costing them money? Sheesh.
Thanks for the quick response - so IR still sucks - doubtful I'll be able to find an email addy for Denner himself, but I might find one for Sarissa.
Unbelievable - AMRN is desperate to stay relevant in the US, but they aren't making enough 0.5 g caps to keep pharmacy shelves stocked!?! Tried to get my monthly scrip filled at CVS yesterday - they tried bait and switching me to GV again (my Part D insurance doesn't cover GV!) - I refused it, said give me brand name V, they didn't have it, ordered it and said it would be in today. I just got back from CVS - not only was my V scrip not ready, I couldn't even get it - 0.5 g V is on backorder with no timeline for when their distributor will get it. CVS is what, the largest or 2nd largest pharmacy chain in the US, but AMRN can't keep them supplied with 0.5 g V?!?!? WTF is wrong with this company besides everything?
I'm so mad personally - sometimes I gag on the 1 g caps, but I had to get them today because I've already been w/o V for 2 days - and I'm mad as a shareholder - has anyone had any luck getting responses if they email IR? I want to contact them and bitch about this debacle if it's worth my time, otherwise will quietly stew. Oh, and boy I had no idea how much more expensive 0.5 g was vs. 1 g - I knew it cost more, but I only paid HALF of what the 0.5 g caps cost - I'm in the donut hole, have been since my last V refill, and that last 0.5 g 1 mo scrip cost me $100 - today I only paid $50 for the 1 g caps - over the span of a year that's probably close to a $1000 diff.in out of pocket costs for me, and it's costing AMRN $&*#% money they desperately need - this is BULLSHIT. Anyone got Denner's email addy?
Nice patent, but essentially useless unless AMRN intends to run new trials with this new lecithin containing formula to show getting EPA into organs via the lymph system can help the disease state of multiple organs, I assume by reducing organ inflammation, which causes things like pancreatitis, impaired kidney function etc. - there's some stuff in the patent suggesting this use would be for cancer, but it doesn't say how EPA could treat cancer. That patent says there's a Fig. 22 that shows how much this new formula increased EPA levels in organs of rats but there are no figures in this file:
https://patents.google.com/patent/WO2023146984A1/en?oq=WO2023146984
Ah - if you download the PDF (link is at top of page) you can see the figures - check pg 169 for Fig 22 - pretty shocking how such a tiny amount of lecithin can increase EPA in organs - for the brain it was +80%, in the lungs by > 100% - it could have helped patients in COVID and BRAVE trials .
The patent is basically too broad - they would have a dozen or more diseases to look at, and they'd have to pick the best one since they can't afford a hit and miss - my money says they don't do more the preclinical work with mice or rats for a year or more. Then taking it all the way to FDA/EMA approval is more money AMRN can't afford unless EU V sales actually start to contribute to earnings, whenever THAT'S going to happen - and I don't mean revs, I mean profits - the level where V sales cover the costs of their EU operations I haven't a clue. Overall, I think we can stick this into the "nice to have but we'll never use it for anything" patent pile, which is pretty damn high at this point.
Here's the relevant section of the patent for increasing EPA in organs:
Italy refusing to pay for V is a BIG FSCKING DEAL! They're one of the top 5 EU markets - now AMRN is blocked from 2 of them, including Germany. This is why nobody wants to buy them out - not much money to be made, too many countries refusing to pay.
Not new to biotechs - I'm one of the few remaining original members of this MB.
Yeah, such big news AMRN didn't even bother to issue a PR about it - that's either IR falling flat on their face, or AMRN knows this has no real value - if they have no intention of testing it, which is almost certainly the case, then it means nothing except blocking some other company from combining GV with a PPAR to create a new drug. But adding a fibrate type drug comes with the exact same problem that a V+statin drug poses - too many different drugs to choose from and too many doses with each drug - there is no "one size fits all" combo drug regardless of what you choose to be the add-on drug.
Heck, even V is a compromise at 4 g/day - a 110 lb woman will have a much larger amount of serum EPA than a 280 lb man - if excess EPA is just excreted, no problem for the woman except wasted money, but that man is likely not getting the full benefit of V since he has a much lower concentration of EPA in his blood - about half as much as the woman. From https://www.omnicalculator.com/health/blood-volume , a 5'2" 110 woman has 3225 ml of blood, while a 6'0" 280 lb man has more than double the amount of blood, 6937 ml - they will clearly have a ~50% difference in EPA concentration in their blood before it's absorbed by cells. But it would have been too expensive to add a 6 g/day arm to R-IT, costs would have gone up significantly (> $100M), assuming they added patients to get good p values instead of splitting the 8000 patients into 3 smaller groups.
Amarin has multiple next generation Vascepa-Plus in the works
Since when? They've only talked about a V + statin combo drug in the past - I haven't seen this new patent yet, but it could be just a way to prevent generics from making a different combo drug - not that AMRN has any intention of spending the money needed to actually run a trial and try to get it FDA approved. Hell, they've had the statin combo patent for many years and haven't done a damn thing with it, beyond maybe some pre-clinical petri dish studies.
Don't know why this combo discussion has come up again - it's never going to happen, AMRN can't afford to run a trial necessary to get it approved, and I'll repeat that there is no one size fits all statin or statin dose - a patient could actually do worse on V+ if it contains less statin than he/she's already taking. Which brings me to the point of this post - what you suggest, requiring pharmacies contact doctors if a patient shows up with a scrip for V and a statin to get GV for R-IT, is literally impossible - pharmacies are so short staffed they are having problems filling prescriptions - no way in hell could they take the time to call doctors to talk to them about why this or that was prescribed - and it's none of their business anyway. Plus, most new V patients will already be on a statin - they got a V script because their cardio thought it could help them on top of the statin. I find it hard to believe there's a patient out there who shows up at his PCP to get a physical with bloodwork/EKG/stress test and suddenly discovers he has CVD, he gets referred to a cardio, who prescribes V and a statin. Actually, I do know such patients exist, but they're rare because they're ignorant and stupid - despite knowing my family has a history of CVD, my little brother didn't even go to the doctor for checkups to see if he had HeFH, which my older brother and Dad have (both also had MI's and stents) - he just didn't want to know, probably scared of the answer (that's the stupid part - hiding your head in the sand) - then he had an MI a few summers ago, a couple stents, and is now on a statin - many docs still don't know about or believe the V story so he didn't get a V script. I've tried to get all 3 on V but gave up trying because it was a waste of time - they'd feign interest but then blow it off after they got home - despite me telling them how wonderfully it works for me - I'm the only male w/o CVD.
Not for R-IT, it's only for MARINE indication:
You're replying to a post I made in 2013 about AMRN, ARNA, and VVUS - WTF? Two of those 3 no longer exist - VVUS went BK, and PFE bought ARNA last year for $100/shr for another drug in their pipeline that had excellent P2 results*** - my 11 yr wait finally paid off, my basis was $40 and I owned a boatload of it in 3 accounts - about the same I have invested in AMRN, but I have zero hope of a similar outcome occurring because of problems everyone here is aware of. I'd love to get at least half the money back that I put in AMRN (pps $3.25), but even that is a stretch at this point - maybe in a couple years when EU and China sales actually amount to real income for AMRN. HLS royalties from sales in Canada are stuck at around $2M/yr, several years after V was approved there.
*** The weight loss drug I bought ARNA for, Belviq, was pulled from the market by FDA over cancer concerns after people had been taking it for years (not many people, sales were terrible and ARNA sold the rights to Easai). What's concerning in this case is ARNA originally got a CRL over tumor concerns in a study they did on rats - they re-examined the data, waved their hands over it, said everything was fine, FDA accepted it, and then later discovered the Adcom's breast cancer worries were real and they should not have approved the drug.
Yeah, me a big dummy sometimes! Been having some major brain farts over the last month or two, like cog function is worse (it is) - I'm building new doors to replace the rotted ones on my shed and I've had at least four "I can't believe you effing made such a stupid mistake!!" issues with my design and assembly so far - worried enough that I talked to one of my PTs about it the other day when I discovered I'd made another big boo-boo. Memory is still very good, so it's not a "whole brain" problem, it just involves thinking and problem solving, especially when math is involved. For some reason I've been sleeping 2 hours less per night than I used to, and while that's usually a good thing when it happens occasionally, whatever is causing it now is definitely affecting cog function, like I'm sleep deprived. It's not a Lyme or EBV flare because those make me sleep an extra two hours per day. I recently discovered legal CBD gummies that contain delta 8 or delta 9 extracts, and they make my short term memory vaporize for the next few hours after I take even half of one - although I only take 1/4 or 1/2 of one once or twice a week to help me relax at night I think they may be having long lasting affects on my brain function. Don't smoke pot so don't know if that would have the same affect, but it didn't when I was young (stopped in my late 20's). But I'll get the chance to find out if I want to starting July 1 - my state made recreational THC products legal, and the same law banned CBD products - the pot lobbyists didn't want any competition for customers who use CBD so they put the CBD product growers/sellers out of business. I'll probably run an experiment - put away the concentrated delta 8/9 gummies and try some THC gummies to see if they have the same long term effect - if yes, it's back to drinking some alcohol to relax after a stressful day. Wish I didn't have asthma - can't smoke, can't even breathe second hand smoke w/o having a coughing spasm - I know from hearing on radio talk shows/podcasts about the diff between edibles and smoking is that the edibles are much harder to get a handle on because it takes so long for the full effects to hit you and the effects last hours longer - maybe days longer in my addled brain BTW, there's a great show on the Discovery channel about this business - "Growing Belushi" - it's hilarious (two other comedians are business partners) and educational if you want to know how different strains are created and how the whole process works - it's WAY more complicated when run as a commercial business compared to growing some plants out in a state forest or corn field and selling it on the street. Only part of the increased difficulty is due to meeting regulations and testing requirements - the real problem is these operations are run like assembly line factories - if there's a delay in one process like the growing house it can affect or ruin a month's worth of product (can't get plants into drying and processing houses in time to make room for the next batch of plants), worth $500k in Belushi's case. Sort of like how "just in time" component deliveries killed car manufacturing in the US during the pandemic - assembly lines had to shut down for lack of parts - in the old days they had large inventories of parts on hand, but not anymore.
Thnx for the link (you and CapnBeer) - didn't know he posted that version of the scrip chart on googledrive instead of on StockTwits. Looks to me like V had a small 3 week spike in Jan then fell off, while GV totals went up. But something is odd about that chart - I imported it into PowerPoint to put gridlines on it so I could guesstimate scrip numbers, and it looks like V dropped from ~66k/wk to an avg of ~60k/wk (see chart below). But I noticed something odd after I put in the monthly gridlines - by my count, there's either 12 or 13 data points per month - that's not possible, should only be 4 or 5.
Thnx - can you check my latest reply to JRoon71 (read his post first) and explain the possible discrepancy I see in the number of data points/mo?
I look at CaptBeer's scrip charts every once in a while, not clear to me that market share has flatlined - in fact, Hikma scrips have gone down since this new player "Nstar", whoever the hell that is, joined the fray. I swear he used to plot totals of all GV + V so we could see how total IPE sales varied over time (for a while totals were rising slightly), but that data is not in his latest plots.
So paging CaptBeer - can you put the V+GV totals back on the chart again?
Thanks for letting me know it's not worth my time to read the CC transcript. Decreasing margins are a major problem, and they lost quite a bit of market share in Q1 compared to Q4/22 - they were holding steady for a while around 63%, now down to 57% - that's really, really bad - lower margins and less sales is a road to disaster unless they can reverse the slide, which I don't believe they can. BTW, read in another post of yours you have 175k shrs - if that's true, hope you're independently wealthy or your basis is very, very low, like a buck fifty, because it's money you not likely to recover the way things are going.
Totally agree only USPTO should make these decisions - the problem is they don't have the authority to impose financial penalties or decide whether certain vague statements count as encouraging patent infringement, only judges and courts can do that. In any case, the USPTO isn't infallible - recall the ridiculous patents granted for "inventing" playlists and podcasting that got Adam Carolla in hot water about 4 yrs ago - the TX court said they were valid too. How do you patent an idea like podcasting?
Website doesn't look sketchy to me, for a private company in India - download their product list
http://www.softgelhealthcare.com/SGCTA.PDF
They make OTC drugs (pain relievers and anti-fungals) and all sorts of DS, all in softgels - website says Rx too, but they currently don't make any. But check out who responded to that Linkedin post Captbeer mentioned - one of them is
DIWAKAR CHAUHAN
SECTION HEAD PRODUCTION
Dr. Reddy's Laboratories
I wonder if this "New Formulation on Icosapent Ethyl capsules 0.5 gram" means they created a new encapsulation method that improves the current GV's shelf life to 1 yr vs. V's 4 yrs?
Sure looks like it from the text in that post:
We've thought AMRN had winning arguments in all the litigation they've been involved in, but they lost every case and appeal. Legal justice and AMRN don't belong in the same sentence. But tiny ABUS just got a judge to agree with them that MRNA should be sued for patent infringement, not the US government, as MRNA argued - ABUS is a nobody - why did they get a judge who seems to understand patent law when AMRN can't get one anywhere in the country? Excerpts from an Endpoints.com article about this new development:
Nevermind - Jas mentioned there's a new link to edit a post, just figured out how to do it.
Forgot to mention ain't it ironic that reporter called generic V a "generic heart drug"? It's only a heart drug for R-IT, not high TGs.
Also, IHUB has changed something - I wanted to edit that first post to add the sentence above but there was no way to do it - saw the words "keep", put the cursor on it, and it said "premium members only" - can we no longer edit our posts within 15 minutes?
Thought I had you on ignore......for such meaningless posts such as that one.
Thnx for pointing out that post - exactly what I was looking for - but the numbers don't add up - take the vote tally for Mark DiPaolo - 179M for, 54M against, total is 233M out of 400M shr float (58%), and his chart shows almost no abstentions. in a contested election, there are no broker non-votes - an abstentions *is* a vote, means I decline to vote yes or no. Sort of like how my Dad recently explained himself after looking at some retirement communities over the last few weeks and not liking any of them - he said "making no decision is a decision in itself".